Anika Therapeutics (ANIK) Research & Development (2010 - 2026)

Anika Therapeutics (ANIK) has reported Research & Development for 17 consecutive years, with $7.3 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Research & Development rose 16.28% year-over-year to $7.3 million in Q2 2026; TTM through Jun 2026 was $27.5 million, a 10.58% increase from a year earlier, with the FY2025 full-year figure at $25.8 million, up 0.88% from the prior year.
• Research & Development was $7.3 million for Q2 2026 at Anika Therapeutics, up from $6.7 million in the prior quarter.
• Over five years, Research & Development peaked at $8.9 million in Q2 2023 and troughed at -$3.3 million in Q4 2023.
• A 5-year average of $5.9 million and a median of $6.6 million in 2024 frame the typical range for Research & Development.
• Across the five-year window, Research & Development plunged 135.2% in 2022 and surged 294.7% in 2024, its largest moves.
• Over 5 years, Research & Development stood at -$2.1 million in 2022, then tumbled by 58.24% to -$3.3 million in 2023, then surged by 294.7% to $6.5 million in 2024, then slipped by 0.85% to $6.5 million in 2025, then gained by 13.78% to $7.3 million in 2026.
• The last three Research & Development figures came in at $7.3 million (Q2 2026), $6.7 million (Q1 2026), and $6.5 million (Q4 2025), per Business Quant data.